Back to search

Peptide record

TPDB25410

ABP-dHC-Cecropin A-K(24) Antibacterial Anticancer Toxicity standard
37 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB25410
ABP-dHC-Cecropin A-K(24)
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia CancerPPD 2.0 dbACP pep-lab
standard
No
A 37-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia, CancerPPD 2.0, dbACP, and other sources, with an available 3D structural model.
Sequence
RWKIFKKIERVGQNVRDGIIKAGKAIQVLGTAKALGK
Physicochemical Analysis
C186H321N57O46
CHMPSY
K
4091.95
11.66
10
2
16
+8
8.26
-0.249
108.11
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
5500
134.41
4
Residue Composition
number
4
A
3
R
1
N
1
D
0
C
1
E
2
Q
5
G
0
H
5
I
2
L
7
K
0
M
1
F
0
P
0
S
1
T
1
W
0
Y
3
V
Amino Acid Distribution
A: 4 R: 3 N: 1 D: 1 C: 0 E: 1 Q: 2 G: 5 H: 0 I: 5 L: 2 K: 7 M: 0 F: 1 P: 0 S: 0 T: 1 W: 1 Y: 0 V: 3
Chemical Descriptors
37
C186H321N57O46
4091.95
11.66
+8
8.26
-0.249
Free
L
Linear
Free
Host Defence Peptide
Synthetic
Evidence Records 7 records
Evidence 1 Activity

Activity

IC50
IC50 = 184.9 µM
Anticancer
184.9 µM

Target

Leukemia Cancer
K-562
Blood

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2017

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 223.9 µM
Anticancer
223.9 µM

Target

Leukemia Cancer
U-937
Blood

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2017
Evidence 3 Activity

Activity

IC50
IC50 = 196.1 µM
Anticancer
196.1 µM

Target

Leukemia Cancer
THP-1
Blood

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2017
Evidence 4 Activity

Activity

Toxicity
Cytotoxic
- | NA | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Selective cytotoxicity of the antibacterial peptide ABP-dHC-Cecropin A and its analog towards leukemia cells. | Eur J Pharmacol | 2017
Evidence 5 Activity

Activity

Toxicity
Cytotoxic
- | NA | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Selective cytotoxicity of the antibacterial peptide ABP-dHC-Cecropin A and its analog towards leukemia cells. | Eur J Pharmacol | 2017
Evidence 6 Activity

Activity

<5% Hemolysis
Toxicity
800 µM
Hemolytic Cytotoxic
<5% Hemolysis | 800 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Selective cytotoxicity of the antibacterial peptide ABP-dHC-Cecropin A and its analog towards leukemia cells. | Eur J Pharmacol | 2017
Evidence 7 Activity

Activity

IC50
Toxicity
184.9 µM
Hemolytic Cytotoxic
Hemolytic_activity: [Ref.28347740] 0% hemolysis at 0µM, 1% hemolysis at 800µM against human red cells | Cytotoxicity: [Ref.28347740] IC50 = 184.9 µM and CI = [185.3, 191.0] µM against K562 cells. ## IC50 = 223.9 µM and CI =[211.4, 236.5] µM against U937 cells. IC50 = 196.1 µM and CI = [170.2, 222.1] µM against THP-1 cells. The CI is the Confidence Interval of 90%.

Target

erythrocytes

Source & Reference

NA
DRAMP
Eur J Pharmacol. 2017 May 15 803:138-147.